Article

Multiple Low Dose (MLD) therapy: an effective strategy to treat EGFR inhibitor-resistant NSCLC tumours

2019-10-29

Abstract excerpt

Targeted cancer drugs often elicit powerful initial responses, but generally fail to deliver long-term benefit due to the emergence of resistant cells 1,2 . This is thought to be the consequence of strong selective pressure exerted on the cancer drug target by a Maximum Tolerated Dose (MTD) of a drug 3–5 . We hypothesized that partial inhibition of multiple components in the same oncogenic signalling pathway mig...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 59efb10b-a3fb-567e-b714-c9b1a7d54750
DOI: 10.1101/821975

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 8 closest

Multiple Low Dose (MLD) therapy: an effective strategy to treat EGFR inhibitor-resistant NSCLC tumoursDOI 10.1101/821975Read

Multiple low dose therapy as an effective strategy to treat EGFR inhibitor-resistant NSCLC tumours.Semantic proximity Read

Dose-Dependent Mutation Rates Determine Optimum Erlotinib Dosing Strategies for EGFR Mutant Non-Small Cell Lung Cancer Patients.Semantic proximity Read

Experimental Determination of Cancer Drug Targets with Independent Mechanisms of Resistance.Semantic proximity Read

Challenge and countermeasures for EGFR targeted therapy in non-small cell lung cancer.Semantic proximity Read

A Combination of Approved Antibodies Overcomes Resistance of Lung Cancer to Osimertinib by Blocking Bypass Pathways.Semantic proximity Read

Management of tyrosine kinase inhibitor resistance in lung cancer with EGFR mutationSemantic proximity Read

Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors.Semantic proximity Read

Novel Third-Generation EGFR Tyrosine Kinase Inhibitors and Strategies to Overcome Therapeutic Resistance in Lung CancerSemantic proximity Read